InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...

One of the world’s largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

October 22, 2008--MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that it has submitted its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration ...

DUBLIN - July 17, 2017 - Medtronic plc (MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life ...

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

One of the world's largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...